Exploring MRD and Venetoclax in Chronic Lymphocytic Leukemia Treatment

This chapter delves into the importance of minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) patients, revealing better outcomes for those with undetectable MRD. It also examines therapy strategies, including intermittent treatments and the role of venetoclax, while addressing data gaps in treatment approaches.